 |
The 130th Annual Meeting of APHA |
|
The 130th Annual Meeting of APHA |
4172.0: Tuesday, November 12, 2002: 2:30 PM-4:00 PM | |||
Oral | |||
| |||
| In the early 90s, researchers recognized the need for early interventions to prevent the spread of bloodborne pathogens such as HIV, hepatitis B and hepatitis C viruses among injection drug users (IDUs). Since then, studies were conducted that attempted to assess the circumstances surrounding initiation of injection drug use, HIV-associated sexual and injection risk behaviors, social network factors, and sociodemographic characteristics of recently initiated IDUs. Given most IDUs do not enter drug treatment programs until they are many years into their addiction, investigators shifted from clinic-based to street-based strategies for recruiting recent-initiate IDUs as study participants. Furthermore, given that median age of initiation is around 19 years, age is a common eligibility criterion for screening out longer-term injectors. In 1997-1999, The Centers for Disease Control and Prevention funded the Second Collaborative Injection Drug Users Study (CIDUS 2) to estimate the prevalence and incidence of HIV, HBV and HCV infections among new injectors and identify behaviors that increase their risk for these infections. This is the Nations largest multisite cohort study of new IDUs that recruited participants who were 18-30 year old or had been injecting for less than 5 years and included Baltimore, Chicago, Los Angeles, New Orleans, and two sites in New York (East Harlem and the Lower East Side). This session will include recent findings from this data set as well as two other studies that recruited from similar populations in Seattle, WA, and Russia. This session is intended to provide the audience with recent findings related to HIV risk among young and recently initiated IDUs | |||
| Learning Objectives: In the early 90s, researchers recognized the need for early interventions to prevent the spread of bloodborne pathogens such as HIV, hepatitis B and hepatitis C viruses among injection drug users (IDUs). Since then, studies were conducted that attempted to assess the circumstances surrounding initiation of injection drug use, HIV-associated sexual and injection risk behaviors, social network factors, and sociodemographic characteristics of recently initiated IDUs. Given most IDUs do not enter drug treatment programs until they are many years into their addiction, investigators shifted from clinic-based to street-based strategies for recruiting recent-initiate IDUs as study participants. Furthermore, given that median age of initiation is around 19 years, age is a common eligibility criterion for screening out longer-term injectors. In 1997-1999, The Centers for Disease Control and Prevention funded the Second Collaborative Injection Drug Users Study (CIDUS 2) to estimate the prevalence and incidence of HIV, HBV and HCV infections among new injectors and identify behaviors that increase their risk for these infections. This is the Nations largest multisite cohort study of new IDUs that recruited participants who were 18-30 year old or had been injecting for less than 5 years and included Baltimore, Chicago, Los Angeles, New Orleans, and two sites in New York (East Harlem and the Lower East Side). This session will include recent findings from this data set as well as two other studies that recruited from similar populations in Seattle, WA, and Russia. This session is intended to provide the audience with recent findings related to HIV risk among young and recently initiated IDUs | |||
| See individual abstracts for presenting author's disclosure statement and author's information. | |||
| Richard S Garfein, PhD, MPH | |||
| Richard S Garfein, PhD, MPH | |||
| HIV risk among young adult injection drug users: Recent findings from the Second Collaborative Injection Drug Users Study (CIDUS 2) and similar studies (SESSION ABSTRACT) Richard S Garfein, PhD, MPH | |||
| Correlation between housing changes and HIV risk behaviors among young injection drug users (IDUs) Laura Broyles, MD, Theresa Perlis, PhD, Peter Kerndt, MD, MPH, Edward V Morse, PhD, Lawrence Ouellet, PhD, S.A. Strathdee, PhD, David Vlahov, PhD, Roberto Valverde, MPH, Andrea Swartzendruber, Richard S Garfein, PhD, MPH | |||
| Family system characteristics associated with young IDUs' high risk injecting practices Edward V Morse, PhD, Patricia M Morse, PhD, Sam Burgess, MA | |||
| Association of select drug use behaviors and duration of drug use among newly initiated injection drug users Meredith Becker Buxton, MPH, David Vlahov, PhD, S.A. Strathdee, PhD, Don C. Des Jarlais, PhD, Edward V Morse, PhD, Lawrence Ouellet, PhD, Peter Kerndt, MD, MPH, Richard S Garfein, PhD, MPH | |||
| Correlates of HIV infection among young new initiates to injection drug use in Baltimore, Maryland: 1994-2000 Mahboobeh Safaeian, MPH, Meg Doherty, MD PhD, Crystal Fuller, MPH, PhD, Susan G. Sherman, MPH, PhD, Danielle C. Ompad, MHS, David Vlahov, PhD, S.A. Strathdee, PhD | |||
| Young age vs. years injecting: A birth cohort analysis of HIV risk in Seattle IDUs Holly Hagan, PhD, Hanne Thiede, DVM, MPH | |||
| Drug use and HIV risk behavior among syringe exchange participants in Eastern Europe and the U.S Don Des Jarlais, PhD | |||
| Organized by: | Alcohol, Tobacco, and Other Drugs | ||
| Endorsed by: | Epidemiology; HIV/AIDS; School Health Education and Services; Socialist Caucus | ||
| CE Credits: | CME, Health Education (CHES), Nursing, Pharmacy, Social Work | ||